Dear Sir,
People who live and work in cold areas have a higher incidence of hypertension and related cardiovascular diseases and mortality compared to those living in warmer areas, 1, 2 and cold exposure is a risk factor for hypertension. 3 Cold winter weather is associated with more severe hypertension, stroke and myocardial infarction in hypertensive patients. 2, 4 Seasonal variation of blood pressure (BP), with the highest values during the cold season, has been well documented. 5, 6 Both local and wholebody cold exposure increase BP. [7] [8] [9] In the northern part of the world, people are exposed to low outdoor temperatures while going to work and occasionally also during leisure time. Moreover, there are still many occupations involving part-or full-time outdoor work.
Metoprolol is widely used as a treatment for hypertension, but there is no published information about the effects of metoprolol in whole-body cold exposure. The aim of the present study was to test the effects of metoprolol on BP and heart rate (HR) in hypertensive subjects during whole-body cold exposure, simulating normal outdoor winter cold exposure.
The study protocol was approved by the Ethics Committee of the Medical faculty at the University of Oulu. The subjects were informed about the test and they gave their written consent. A total of 12 healthy volunteers o45 years with diastolic BP (DBP) between 90 and 105 mmHg and/or systolic BP (SBP) higher than 140 mmHg as measured several times during the last year, were measured by 24-h ambulatory blood pressure monitoring (ABPM) to confirm the elevated BP. Five subjects were excluded from the study: two because of the white-coat phenomenon, two did not follow the study protocol and one had a respiratory infection with fever during the weeks of the test procedures. The final study group comprised seven subjects. Their mean age was 30 years (s.d. 9), mean weight was 71 kg (s.d. 15), mean height 171 cm (s.d. 8) and mean body mass index 24 kg/m 2 (s.d. 5). During 24-h ABPM the mean daytime (7-23) BP 34%/58% of daytime measurements (timeload) were over 135/85 mmHg.
The tests were carried out during the winter in a climate chamber and wind tunnel. The test subjects were exposed to cold (À151C, wind 3.5 m/s) three times for 15 min. After an initial exposure aimed at familiarisation, the second and third exposures were arranged at the same time (1000 hours) in a random double-blind, crossover pattern after a week's ingestion of metoprololtartrate 100 mg (Selopral s ) or placebo once a day.
The study procedures were carried out as described in detail by Komulainen et al. 9 Briefly, the subjects wore winter clothing with thermal insulation of ca. 2 clo (long underwear, trousers, boots, hat and a winter coat). The test subjects sat for 15 min on a chair in a climatic chamber (air temperature (T a ) 181C, air velocity (V a ) o0.2 m/s and relative air humidity 50%) without any movement or talking. Thereafter, the subjects put on a cap, gloves, and a scarf and closed the zipper of the winter coat and walked slowly 5 m to the wind tunnel. Subjects sat there (T a À151C, V a 3.5 m/s and relative air humidity 50%) on a chair for 15 min without any movement or talking. After the cold exposure, the subjects walked slowly back to the climatic chamber and sat there for 15 min. Subjective ratings of thermal sensation 10 and cold pain (7-point scale) were asked just before the cold exposure and three times during the cold exposure. BP and HR were measured oscillometrically every 3 min during the test from the right upper arm using an indirect ambulatory blood pressure monitor device (Meditech ABPM-02, Meditech Co., Hungary).
Compared to placebo, metoprolol decreased BP (Table 1 ) significantly in the test group before the cold exposure. During the cold exposure, BP increased rapidly. At 3 min after the start of the cold exposure, SBP/DBP increased from a 118/77-mmHg base level to 139/93-mmHg with metoprolol and from 129/86 to 151/102 mmHg with placebo. BP was significantly lower with metoprolol than placebo during the cold exposure. During the cold exposure, SBP/DBP reached peak values at 147/ 100 mmHg with metoprolol. BP was significantly lower with metoprolol than with placebo after the cold exposure. BP decreased slowly after the cold exposure, and BP remained elevated during the 15-min recovery period after the cold exposure both with placebo and metoprolol.
The cold-induced increase in BP was not significantly affected by metoprolol. The mean increase in SBP/DBP was 24/19 mmHg higher with metopro-lol and 23/17 mmHg higher with placebo during the cold exposure in comparison to mean SBP/DBP before cold exposure. The peak cold-induced rise of the SBP/DBP was 29/23 and 34/22 mmHg with metoprolol and placebo, respectively.
Metoprolol decreased HR before, during and after cold exposure compared to placebo (Table 1) . Metoprolol did not affect general or local thermal sensations during cold exposure. Thermal sensations were described as 'cold' in general, as 'cold' in feet and as 'cool' in hands and the cold pain as 'no pain' both during metoprolol and placebo.
Metoprolol lowered mean and peak BP significantly, but it did not prevent the cold-induced rise of the BP during cold exposure that simulated normal outdoor exposure in winter. Carvedilol, 9 which was studied earlier in the same test procedures, decreased the level of BP slightly more than metoprolol, while the amount of cold-induced rise of BP was on the same level. The present results with mildly hypertensive subjects differ from previous studies with healthy subjects: DBP 11 and MAP 12 were higher with atenolol and propranolol compared to placebo and the amount of coldinduced rise was greater than with placebo during cold exposure.
According to the present study, metoprolol seems to be an effective antihypertensive drug also during short cold exposure in borderline hypertensive subjects. Metoprolol did not prevent physiological BP response in cold, neither did it affect thermal sensations in adequately clothed subjects during a short cold exposure. 
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